MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its holdings in MacroGenics, Inc. (NASDAQ:MGNX) by 13.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 803,375 shares of the biopharmaceutical company’s stock after selling 126,701 shares during the period. Federated Hermes Inc. owned approximately 1.30% of MacroGenics worth $7,728,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. RA Capital Management L.P. purchased a new stake in shares of MacroGenics in the 3rd quarter valued at approximately $1,594,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of MacroGenics in the 3rd quarter valued at approximately $649,000. Acadian Asset Management LLC boosted its position in shares of MacroGenics by 7.8% during the 3rd quarter. Acadian Asset Management LLC now owns 1,371,396 shares of the biopharmaceutical company’s stock worth $6,388,000 after purchasing an additional 99,755 shares during the period. GSA Capital Partners LLP boosted its position in shares of MacroGenics by 74.9% during the 3rd quarter. GSA Capital Partners LLP now owns 225,918 shares of the biopharmaceutical company’s stock worth $1,053,000 after purchasing an additional 96,760 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in shares of MacroGenics during the 3rd quarter worth approximately $281,000. Institutional investors and hedge funds own 96.89% of the company’s stock.

Insider Buying and Selling

In related news, SVP Ezio Bonvini sold 13,316 shares of MacroGenics stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $15.00, for a total transaction of $199,740.00. Following the sale, the senior vice president now directly owns 74,668 shares in the company, valued at approximately $1,120,020. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Ezio Bonvini sold 13,316 shares of MacroGenics stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $15.00, for a total transaction of $199,740.00. Following the sale, the senior vice president now directly owns 74,668 shares in the company, valued at approximately $1,120,020. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jeffrey Stuart Peters sold 51,395 shares of MacroGenics stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $15.55, for a total transaction of $799,192.25. The disclosure for this sale can be found here. Insiders have sold 80,835 shares of company stock worth $1,276,588 in the last ninety days. 11.30% of the stock is owned by corporate insiders.

MacroGenics Trading Down 3.3 %

Shares of MGNX opened at $15.70 on Thursday. MacroGenics, Inc. has a twelve month low of $4.29 and a twelve month high of $21.88. The firm’s fifty day simple moving average is $16.82 and its 200-day simple moving average is $11.86. The firm has a market capitalization of $982.19 million, a price-to-earnings ratio of -98.13 and a beta of 2.09.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.49). MacroGenics had a negative net margin of 15.42% and a negative return on equity of 88.49%. The firm had revenue of $10.72 million during the quarter, compared to analyst estimates of $25.70 million. During the same quarter in the previous year, the business posted $0.21 earnings per share. On average, analysts predict that MacroGenics, Inc. will post -2.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on MGNX shares. TheStreet cut shares of MacroGenics from a “c” rating to a “d” rating in a research report on Thursday, March 7th. TD Cowen raised shares of MacroGenics from a “hold” rating to a “buy” rating in a research report on Tuesday, April 9th. Barclays increased their price objective on shares of MacroGenics from $12.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. JMP Securities reaffirmed a “market outperform” rating on shares of MacroGenics in a research report on Thursday, April 4th. Finally, BTIG Research increased their target price on shares of MacroGenics from $12.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, MacroGenics currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.